Kenneth Cusi, MD

Kenneth Cusi, MD, FACP, FACE - Research & Publications

(352) 273-8655

Request an Appointment

Publications

Pioglitazone Improves Hepatic Mitochondrial Function in a Mouse Model of Nonalcoholic Steatohepatitis
American Journal of Physiology-Endocrinology and Metabolism
2018

Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
Diabetes Care
2018

Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
American journal of physiology. Endocrinology and metabolism
2018

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases
Hepatology
2018

Design and Rationale for a Real-World Observational Cohort of Patients With Nonalcoholic Fatty Liver Disease: the Target-Nash Study
Contemporary Clinical Trials
2017

Favorable Outcome of Hurthle Cell Carcinoma of the Thyroid Treated With Total Thyroidectomy, Radioiodine, and Selective Use of External-Beam Radiotherapy
American Journal of Clinical Oncology-Cancer Clinical Trials
2017

Metabolic and Histological Implications of Intrahepatic Triglyceride Content in Nonalcoholic Fatty Liver Disease
Hepatology
2017

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: a Call to Action
Diabetes Care
2017

Nonalcoholic Fatty Liver Disease the New Complication of Type 2 Diabetes Mellitus
Endocrinology and Metabolism Clinics of North America
2016

Prediabetes a Worldwide Epidemic
Endocrinology and Metabolism Clinics of North America
2016

Pharmacological Management of Nonalcoholic Fatty Liver Disease
Metabolism-Clinical and Experimental
2016

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
Diabetes Care
2016

Lipotoxicity in Steatohepatitis Occurs Despite An Increase in Tricarboxylic Acid Cycle Activity
American Journal of Physiology-Endocrinology and Metabolism
2016

Plasma Thyroid Hormone Concentration Is Associated With Hepatic Triglyceride Content in Patients With Type 2 Diabetes
Journal of Investigative Medicine
2016

Clinical Value of Liver Ultrasound for the Diagnosis of Nonalcoholic Fatty Liver Disease in Overweight and Obese Patients
Liver International
2015

Cross-Talk Between Branched-Chain Amino Acids and Hepatic Mitochondria Is Compromised in Nonalcoholic Fatty Liver Disease
American Journal of Physiology-Endocrinology and Metabolism
2015

The Role of Liver Fat and Insulin Resistance as Determinants of Plasma Aminotransferase Elevation in Nonalcoholic Fatty Liver Disease
Hepatology
2015

Multivariate Analysis of Factors That Influence Improvement in Nonalcoholic Fatty Liver Disease (Nafld) After Pioglitazone Treatment.
Pharmacotherapy
2014

The Relationship Between Hepatitis C Virus Infection and Diabetes: Time for a Divorce?
Hepatology
2014

A Validated Liquid Chromatography Tandem Mass Spectrometry Method for Simultaneous Determination of Pioglitazone, Hydroxypioglitazone, and Ketopioglitazone in Human Plasma and Its Application To a Clinical Study
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
2014

Pharmacodynamic Association of Pioglitazone and Its Active Metabolites With Liver Outcomes Among Patients Diagnosed With Nonalcoholic Steatohepatitis.
Clinical Pharmacology \& Therapeutics
2014

The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Current Diabetes Reports
2013

Metabolic and Histological Effects of Liver Fat Accumulation in Patients With Nash
Higher Education Policy
2012

Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (Nafld)
Diabetes Care
2012

Challenges and Opportunities in the Management of the Hispanic/Latino Patient With Type 2 Diabetes Mellitus Introduction
American Journal of Medicine
2011

Unmet Needs in Hispanic/Latino Patients With Type 2 Diabetes Mellitus
American Journal of Medicine
2011

Focus On Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies Introduction
Endocrine Practice
2011

Focus On the Type 2 Diabetes Patient With Liver Disease: Emphasis On Nonalcoholic Fatty Liver Disease (Nafld)
Endocrine Practice
2011

Research Interests

Dr. Cusi is the principal investigator of a number of ongoing clinical research projects. His grants focus on cutting-edge research in adult endocrinology, diabetes and metabolism, both on clinical and basic research aspects related to the role of obesity and lipotoxicity in the development of Type 2 diabetes and its complications, in particular, the pathogenesis of NAFLD. He has published more than 90 original articles, invited reviews and book chapters in the main journals in the fields of obesity, diabetes and liver disease. Dr. Cusi is a nationally and internationally recognized investigator and speaker on the impact of NAFLD in humans, including a frequently cited paper in the New England Journal of Medicine on the first effective pharmacological agent for the treatment of NAFLD, a common and potentially serious complication of obesity and T2DM that may lead to severe liver damage. He is a reviewer in numerous scientific journals. Dr. Cusi is also vice-president and co-founder of Children in Need, Inc., an organization created to assist disadvantaged children and their families in third world countries, with emphasis on hospitals and schools in Southern Africa.